Owner Novartis AG

Inventors Badiger, Sangamesh; Chebrolu, Murali; Frederiksen, Mathias; Holzer, Philipp; Hurth, Konstanze; Li, Lei; Liu, Hui; Lueoend, Rainer Martin; Machauer, Rainer; Moebitz, Henrik; Neumann, Ulf; Ramos, Rita; Rueeger, Heinrich; Schaefer, Michael; Tintelnot-Blomley, Marina; Veenstra, Siem Jacob; Voegtle, Markus; Xiong, Xin

Agent Davies Collison Cave

Pub. Number AU-B-2011278825

PCT Pub. Number WO2012/006953

Priority 61/435,088 21.01.11 US; 61/363,702 13.07.10 US; 61/432,058 12.01.11 US; PCT/ EP2010/060718 23.07.10 EP

Filing date 13 July 2011

Wipo publication date 19 January 2012

Acceptance publication date 20 September 2012

C07D 265/30 Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms

A61K 31/5377

A61K 31/553 - having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine

A61P 9/00 Drugs for disorders of the cardiovascular system

A61P 25/00 Drugs for disorders of the nervous system

C07D 413/12 Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

C07D 417/12 Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

C07D 471/04 Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups